Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
June 08 2022 - 7:33AM
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three
abstracts highlighting data from its hepatitis B virus (HBV)
program have been accepted for one oral and two poster
presentations at the International Liver Congress™ 2022 (ILC),
the Annual Meeting of the European Association for the Study of the
Liver (EASL), taking place in London and online June 22-26.
The oral presentation will highlight new dose
and duration data from a Phase 2 trial evaluating VIR-2218, an
investigational HBV-targeting small interfering ribonucleic acid
(siRNA) that mediates RNA interference, for the potential
functional cure of chronic HBV infection.
One poster presentation will highlight
dose-dependent durability data from a Phase 1 trial of VIR-3434, an
investigational HBV-neutralizing monoclonal antibody designed to
inhibit HBV entry into cells, reduce the number of virions and
subviral particles in the blood, and potentially function as a
therapeutic T cell vaccine. The second poster presentation will
showcase preclinical in vivo data demonstrating that the
combination of VIR-2218 plus VIR-3434 resulted in greater surface
antigen reductions than monotherapy with either therapy.
Presentation details are as follows:
Oral
Presentation:
-
Title: Longer treatment duration of monthly
VIR-2218 results in deeper and more sustained reductions in
hepatitis B surface antigen in participants with chronic hepatitis
B infection (Abstract #644)Session: Viral
Hepatitis: Hepatitis B Emerging TherapiesDate:
Saturday, June 25Time: 8:00 - 9:30 a.m. BST (3:00
- 4:30 a.m. EDT)Presenter: Young-Suk Lim, M.D.,
Ph.D., Professor, Department of Gastroenterology and Liver Center,
Asan Medical Center, University of Ulsan College of Medicine,
Seoul, South Korea
Poster Presentations:
-
Title: Dose-dependent durability of hepatitis B
surface antigen reductions following administration of a single
dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody
(Abstract #654; Poster #SAT434)Date: Saturday,
June 25Time: 9:00 a.m. BST (4:00 a.m.
EDT)Presenter: Kosh Agarwal, M.D., Consultant
Hepatologist and Transplant Physician at the Institute of Liver
Studies at King’s College Hospital, and Clinical Director of the
NIHR South London Clinical Research Network
-
Title: VIR-2218 plus VIR-3434 combination therapy
reduces hepatitis B virus surface antigen levels in vivo (Abstract
#3009; Poster #SAT357)Date: Saturday, June
25Time: 9:00 a.m. BST (4:00 a.m.
EDT)Presenter: Andrea Cathcart, Ph.D., Director,
Clinical Virology, Vir Biotechnology
About Chronic Hepatitis
BChronic hepatitis B virus (HBV) infection remains an
urgent global public health challenge associated with significant
morbidity and mortality. Approximately 300 million people around
the world are living with HBV and about 900,000 die from
HBV-associated complications each year. These patients are
significantly underserved by existing therapies, with low
functional cure rates, lifelong daily therapy and poor
tolerability. Vir Biotechnology is working to achieve a functional
cure for the millions of people with hepatitis B around the world
through its broad and differentiated portfolio.
About VIR-2218VIR-2218 is an
investigational subcutaneously administered HBV-targeting siRNA
that has the potential to stimulate an effective immune response
and have direct antiviral activity against HBV. It is the first
siRNA in the clinic to include Enhanced Stabilization Chemistry
Plus (ESC+) technology designed to enhance stability and minimize
off-target activity, which potentially can result in an increased
therapeutic index. VIR-2218 is the first asset in the Company’s
collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical
trials.
About VIR-3434VIR-3434 is an
investigational subcutaneously administered HBV-neutralizing
monoclonal antibody designed to block entry of all 10 genotypes of
HBV into hepatocytes and reduce the level of virions and subviral
particles in the blood. VIR-3434, which incorporates Xencor’s
Xtend™ and other Fc technologies, has been engineered to
potentially function as a T-cell vaccine against HBV in infected
patients, as well as to have an extended half-life.
About Vir BiotechnologyVir
Biotechnology is a commercial-stage immunology company focused on
combining immunologic insights with cutting-edge technologies to
treat and prevent serious infectious diseases. Vir has assembled
four technology platforms that are designed to stimulate and
enhance the immune system by exploiting critical observations of
natural immune processes. The Company’s current development
pipeline consists of product candidates targeting COVID-19,
hepatitis B and hepatitis D viruses, influenza A and human
immunodeficiency virus. Vir routinely posts information that may be
important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “may,” “will,” “potential,”
“aim,” “expect,” “promise,” “goal,” “anticipate,” “could” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These
forward-looking statements are based on Vir’s expectations and
assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, but are not limited to, statements regarding the
data from its VIR-2218 and VIR-3434 clinical trials, and the
expected ability of VIR-2218 and VIR-3434 (as monotherapies or
combination therapies) to effectively treat and/or prevent chronic
HBV infection. Many factors may cause differences between
current expectations and actual results, including unexpected
safety or efficacy data or results observed during clinical trials,
difficulties in obtaining regulatory approval, difficulties in
collaborating with other companies, challenges in accessing
manufacturing capacity, clinical site activation rates or clinical
trial enrollment rates that are lower than expected, successful
development and/or commercialization of alternative product
candidates by Vir’s competitors, changes in expected or existing
competition, delays in or disruptions to Vir’s business or clinical
trials due to the COVID-19 pandemic, geopolitical changes
(including the ongoing conflict between Russia and Ukraine) or
other external factors and unexpected litigation or other disputes.
Drug development and commercialization involve a high degree of
risk, and only a small number of research and development programs
result in commercialization of a product. Results in early-stage
clinical trials may not be indicative of full results or results
from later stage or larger scale clinical trials and do not ensure
regulatory approval. You should not place undue reliance on these
statements, or the scientific data presented. Other factors that
may cause actual results to differ from those expressed or implied
in the forward-looking statements in this press release are
discussed in Vir’s filings with the U.S. Securities and Exchange
Commission, including the section titled “Risk Factors” contained
therein. Except as required by law, Vir assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
Contacts:
Investors
Heather Rowe Armstrong
VP, Investor Relations
harmstrong@vir.bio
+1 303 641 2052
Media
Cara Miller
VP, Corporate Communications
cmiller@vir.bio
+1-415-941-6746
Vir Biotechnology (NASDAQ:VIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vir Biotechnology (NASDAQ:VIR)
Historical Stock Chart
From Apr 2023 to Apr 2024